Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

LGD-4033 and Winstrol Interaction: Avoid | Peptide Database

Compound Profiles LGD-4033 Selective Androgen Receptor Modulator | Lean Mass LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its t

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Winstrol

DHT-Derived Anabolic Steroid | Cutting & Athletic Performance

Stanozolol exerts its effects through binding to the intracellular androgen receptor (AR), promoting nitrogen retention, protein synthesis, and red blood cell production. As a DHT derivative, it cannot be aromatized by the aromatase enzyme, eliminating estrogen-mediated side effects.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take LGD-4033 with Winstrol?

Combining LGD-4033 with Winstrol is not recommended. Both LGD-4033 and Winstrol carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is LGD-4033 and Winstrol safe together?

This combination carries significant risk. Both LGD-4033 and Winstrol carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between LGD-4033 and Winstrol?

Both LGD-4033 and Winstrol carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time LGD-4033 and Winstrol?

LGD-4033 has a half-life of ~24-36 hours and Winstrol has a half-life of ~9 hours (oral), ~24 hours (injectable). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

Directly activates the master metabolic regulator through ZMP accumulation. Increases fat burning through AMPK-mediated pathways. Enhances glucose uptake independent of insulin in some tissues. Animal studies showed increased running endurance; human data limited. AMPK activation promotes new mitochondria formation over time. Original clinical interest; may protect heart tissue during reduced blood flow.

Source: peptide-db.com ↗

Community Research

Join others researching Enclomiphene — share findings, ask questions, and learn from real experiences Enclomiphene is the trans-isomer of clomifene citrate, a selective estrogen receptor modulator (SERM) that acts primarily as an estrogen antagonist at the hypothalamus and pituitary. Unlike the racemic mixture clomifene (Clomid), which contains both enclomiphene and the cis-isomer zuclomifene, enclomiphene lacks significant estrogenic agonist activity. This makes it better suited for raising endogenous testosterone through increased LH and FSH secretion without the estrogenic side effects commonly associated with clomifene. It was developed under the trade name Androxal for the treatment of secondary hypogonadism in men but has not yet received FDA approval as a standalone product. Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH release. This disinhibition increases pulsatile GnRH secretion, which in turn stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Elevated LH drives Leydig cell testosterone synthesis in the testes, while FSH supports Sertoli cell function and spermatogenesis. Because enclomiphene lacks the estrogenic agonist properties of zuclomifene, it provides cleaner HPTA stimulation without paradoxical estrogenic effects on mood, vision, or other tissues.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Nandrolone is administered exclusively via intramuscular injection. Two ester formulations are available: nandrolone decanoate (Deca-Durabolin), a long-acting ester that permits weekly or biweekly dosing, and nandrolone phenylpropionate (NPP), a shorter ester requiring injections every 2-3 days. Decanoate is more common in clinical and performance settings due to its convenient dosing schedule, while NPP is preferred by those who want faster clearance and more rapid dose adjustments. TRT Adjunct - Joint Support 50-100 mg/week 1x per week (decanoate) Intramuscular Therapeutic - Anemia / Wasting 100-200 mg/week Performance Enhancement - Moderate 200-400 mg/week 1x per week (decanoate) or split into 2 injections NPP Protocol - Shorter Cycle 200-350 mg/week Every other day or 3x per week

Source: peptide-db.com ↗
Side effects

Common Side Effects

Water retention and joint swelling Carpal tunnel syndrome (numbness/tingling) Mild blood glucose elevation Injection site irritation with improper rotation

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides